Home / Market News / $INCY

$INCY news and market catalysts

The 37 most recent market catalysts affecting $INCY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

37 catalysts 4 high impact 30 bullish 1 bearish Pharmaceuticals
Nov 4, 2026 Corporate Catalyst Neutral Impact 55
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte has announced its intention to present new data from its hematology portfolio at the 68th American Society of Hematology (ASH) Annual Meeting in December 2026. This is a rou…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Incyte's Ruxolitinib Phosphate Cream Approved in Singapore for Vitiligo
Rxilient Medical, a subsidiary of CMS, secured approval from the Singapore HSA for ruxolitinib phosphate cream (Lumirix) for non-segmental vitiligo. This is significant as Incyte h…
Oct 30, 2026 Corporate Catalyst Bullish Impact 65
Oppenheimer Upgrades Incyte to Outperform
Oppenheimer upgraded Incyte's stock rating from Market Perform to Outperform and established a price target of $144. This positive re-evaluation by a prominent financial institutio…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
RBC Raises Price Target on Incyte to $117
RBC Capital Markets has raised its price target for Incyte (INCY) to $117 from $114, maintaining a 'Sector Perform' rating. This adjustment is a direct result of the analyst's upda…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
Incyte and Syndax Pharmaceuticals' Niktimvo Performance in Chronic GVHD
The 8-K filing reveals that Niktimvo, a co-developed drug by Incyte and Syndax Pharmaceuticals, generated $67.4 million in sales during Q3 2026. This is significant because it demo…
Oct 29, 2026 Corporate Catalyst Neutral Impact 75
Incyte Reports Third Quarter 2026 Financial Results
Incyte Corporation released its Q3 2026 financial results, a standard but crucial disclosure for publicly traded companies. These reports provide investors with key insights into t…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Incyte and Adagene Initiate Phase 1 Study of Combination Therapy for Colorectal Cancer
Incyte and Adagene announced the commencement of a Phase 1 clinical study for a combination therapy (muzastotug and INCA33890) for third-line microsatellite stable (MSS) colorectal…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Analysts Reiterate Buy Ratings on Incyte (INCY)
Oppenheimer and H.C. Wainwright have both reiterated their 'Buy' ratings on Incyte Corporation. This action signals continued analyst confidence in Incyte's strategic direction and…
Oct 26, 2026 Corporate Catalyst Neutral Impact 75
Incyte Presents New Clinical Data for Oncology Pipeline at ESMO 2026
Incyte presented new clinical data at ESMO 2026, highlighting encouraging efficacy for its KRAS G12D inhibitor, INCB161734, particularly in metastatic pancreatic cancer, and data f…
Oct 14, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Hold on Incyte, Raises Price Target to $115
Truist Securities analyst Srikripa Devarakonda reiterated a 'Hold' rating on Incyte, signifying that the analyst believes the stock is currently fairly valued or that there isn't a…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114
RBC Capital's analyst Brian Abrahams maintained a 'Sector Perform' rating on Incyte but raised the price target from $109 to $114. This action signals a modest increase in the anal…
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Buy on Incyte, Raises Price Target to $157
Stifel analyst Stephen Willey maintained a 'Buy' rating on Incyte and raised the price target from $145 to $157. This action reflects a continued positive sentiment from a reputabl…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152
HC Wainwright & Co. analyst Mitchell S. Kapoor maintained a 'Buy' rating on Incyte and raised the price target from $150 to $152. This action indicates a slightly improved outlook …
Sep 22, 2026 Corporate Catalyst Neutral Impact 55
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Incyte is announcing its plans to present a significant amount of clinical data at the European Academy of Dermatology and Venereology (EADV) conference. The presentations cover mu…
Sep 21, 2026 Corporate Catalyst Bullish Impact 65
Reported Sunday, Specialised Therapeutics To Commercialise, Distribute And Register Incyte's Ruxolitinib Cream (Opzelura) In Australia, Expects To Progress Regulatory And Reimbursement Submissions
The commercialization agreement for Opzelura in Australia is a positive development for Incyte, expanding its global reach and potential revenue streams for a key product. For Spec…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Incyte Announces Agreement With CMS To Offer Jakafi And Jakafi XR To State Medicaid Programs At Prices Aligned With Other Industrialized Nations; Says It Does Not Expect Impact To 2026 Guidance
Incyte's agreement with CMS to align Jakafi pricing with other industrialized nations is a significant development for the pharmaceutical sector. While Incyte claims no impact to i…
Aug 20, 2026 Corporate Catalyst Neutral Impact 55
Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiated coverage on Incyte with a 'Buy' rating and a $152 price target. This is a positive development for Incyte as it signals increased in…
Aug 17, 2026 Corporate Catalyst Bullish Impact 75
Incyte shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $110 to $130.
This headline represents a significant positive corporate catalyst for Incyte. A major investment bank maintaining an 'Overweight' rating and raising the price target by 18% ($110 …
Aug 17, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
This 8-K filing discloses that Piper Sandler, through analyst Allison Bratzel, has maintained an 'Overweight' rating on Incyte (INCY) and raised its price target from $110 to $130.…
Aug 4, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137
Mizuho analyst Salim Syed maintained an 'Outperform' rating on Incyte and raised the price target from $121 to $137. This action signals increased confidence from a prominent finan…
Aug 4, 2026 Corporate Catalyst Neutral Impact 55
Live On CNBC, Josh Brown Host Segment Titled “Josh’s Best Stocks In the Market: Incyte; Biogen"
Josh Brown's endorsement on CNBC, a widely watched financial news channel, can generate significant retail investor attention for Incyte and Biogen. This often translates into incr…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155
Leerink Partners, through analyst Andrew Berens, has maintained an 'Outperform' rating on Incyte (INCY) and raised its price target from $131 to $155. This action signals increased…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109
RBC Capital's analyst Brian Abrahams maintained a 'Sector Perform' rating on Incyte but raised the price target from $99 to $109. This indicates that while the analyst doesn't see …
Jul 29, 2026 Corporate Catalyst Bullish Impact 85
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte (INCY) delivered a robust Q2 performance, exceeding analyst expectations for both earnings and revenue. This positive financial update was further bolstered by the company's…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Incyte, Raises Price Target to $150
Guggenheim's decision to maintain a 'Buy' rating and raise the price target for Incyte suggests increased confidence in the company's prospects. This move typically reflects positi…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130
BMO Capital's analyst Evan Seigerman reiterated a 'Market Perform' rating for Incyte (INCY) but raised the price target from $112 to $130. This action signals a slightly more optim…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Incyte, Raises Price Target to $139
Barclays analyst Etzer Darout has updated their coverage on Incyte, maintaining an 'Overweight' rating and raising the price target from $134 to $139. This action signals increased…
Jul 29, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150
HC Wainwright & Co. maintaining a 'Buy' rating and raising the price target for Incyte indicates a strengthened positive view from the analyst firm. This action is likely based on …
Jul 29, 2026 Corporate Catalyst Bullish Impact 75
Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients
Incyte received European Commission approval for its Opzelura cream to treat moderate atopic dermatitis in adult patients who haven't responded to or can't use standard topical tre…
Jul 28, 2026 Corporate Catalyst Bullish Impact 92
Incyte Says It's No Longer A One-Drug Story
Incyte's Q2 results significantly exceeded analyst expectations for both earnings and revenue, demonstrating strong operational performance. The company's narrative of moving beyon…
Jul 28, 2026 Corporate Catalyst Bullish Impact 92
Incyte shares are trading higher after the company reported better-than-expected Q2 earnings results and raised its FY26 sales guidance.
This headline is a major corporate catalyst for Incyte, as strong earnings and an upward revision to future sales guidance directly impact investor sentiment and valuation models. …
Jul 28, 2026 Corporate Catalyst Bullish Impact 95
Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate
Incyte reported Q2 adjusted EPS of $3.09, significantly beating the $2.12 consensus estimate by 45.75%, and sales of $1.663 billion, surpassing the $1.460 billion estimate by 13.91…
Jul 28, 2026 Corporate Catalyst Bullish Impact 75
Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est
Incyte (INCY) announced an upward revision to its fiscal year 2026 sales guidance, moving from a range of $4.770 billion-$4.940 billion to $5.130 billion-$5.260 billion. This is a …
Jul 14, 2026 Corporate Catalyst Bullish Impact 60
Barclays Maintains Overweight on Incyte, Raises Price Target to $134
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Incyte and raised the price target from $117 to $134. This action signals a strengthened positive outlook from a …
Jul 13, 2026 Corporate Catalyst Bullish Impact 75
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
Incyte announced promising Phase 1/2 data for latarcibart, a once-monthly subcutaneous treatment for von Willebrand disease (VWD). This is a significant development as VWD is the m…
Jul 13, 2026 Market Technicals Bullish Impact 55
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112
BMO Capital's decision to raise Incyte's price target from $94 to $112, while maintaining a 'Market Perform' rating, indicates an updated valuation model by the analyst. This sugge…
Jul 13, 2026 Corporate Catalyst Bearish Impact 75
Incyte Presents Phase 1/2 Multidose Data For VGA039 (Latarcibart) At ISTH 2026, Showing 81% Median Reduction In Annualized Bleeding Rate Across All Von Willebrand Disease Types And Bleed Categories
The positive Phase 1/2 data for VGA039 represents a significant corporate catalyst for Incyte. An 81% median reduction in annualized bleeding rate is a compelling efficacy signal, …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.